Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2

被引:60
作者
Benoit, V
Relic, B
de Leval, X
Chariot, A
Merville, MP
Bours, V
机构
[1] Univ Liege, Ctr Mol & Cellular Therapy, Lab Rheumatol, B-4000 Liege, Belgium
[2] Univ Liege, Nat & Synthet Drugs Res Ctr, B-4000 Liege, Belgium
[3] Univ Liege, Ctr Mol & Cellular Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium
关键词
cyclooxygenase-2; HER-2; erbB-2; prostaglandin; PGE2; cancer;
D O I
10.1038/sj.onc.1207295
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The oncoprotein HER-2/neu is a prosurvival factor and its overexpression has been correlated with adverse prognosis in breast cancers. High levels of the cyclooxygenase-2 (COX-2), a proinflammatory and antiapoptotic enzyme, were detected in HER-2-positive tumors and this observation was linked to an HER-2-mediated induction of COX-2 gene transcription. Here, we report that COX-2 expression, and synthesis of its major enzymatic product, PGE2, leads in turn to an enhanced HER-2 expression. Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab. Therefore, we propose an original model where HER-2 and COX-2 transcriptionally regulate each other in a positive loop.
引用
收藏
页码:1631 / 1635
页数:5
相关论文
共 36 条
[1]  
Baselga J, 1999, SEMIN ONCOL, V26, P78
[2]  
Baselga J, 1998, CANCER RES, V58, P2825
[3]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[4]  
GROOTECLAES M, 1994, CANCER RES, V54, P4193
[5]  
Harris RE, 2000, CANCER RES, V60, P2101
[6]  
Howe LR, 2002, CANCER RES, V62, P5405
[7]   P185HER2 MONOCLONAL-ANTIBODY HAS ANTIPROLIFERATIVE EFFECTS INVITRO AND SENSITIZES HUMAN-BREAST TUMOR-CELLS TO TUMOR NECROSIS FACTOR [J].
HUDZIAK, RM ;
LEWIS, GD ;
WINGET, M ;
FENDLY, BM ;
SHEPARD, HM ;
ULLRICH, A .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (03) :1165-1172
[8]   AMPLIFIED EXPRESSION OF THE HER2/ERBB2 ONCOGENE INDUCES RESISTANCE TO TUMOR NECROSIS FACTOR-ALPHA IN NIH 3T3 CELLS [J].
HUDZIAK, RM ;
LEWIS, GD ;
SHALABY, MR ;
EESSALU, TE ;
AGGARWAL, BB ;
ULLRICH, A ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) :5102-5106
[9]   ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER [J].
HUNG, MC ;
ZHANG, X ;
YAN, DH ;
ZHANG, HZ ;
HE, GP ;
ZHANG, TQ ;
SHI, DR .
CANCER LETTERS, 1992, 61 (02) :95-103
[10]   ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells [J].
Ignatoski, KMW ;
Maehama, T ;
Markwart, SM ;
Dixon, JE ;
Livant, DL ;
Ethier, SP .
BRITISH JOURNAL OF CANCER, 2000, 82 (03) :666-674